Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Antara Datta"'
Autor:
Seock-Ah Im, Antoine Italiano, Jean-Yves Blay, Arun Azad, Victor Moreno, Christine L. Hann, Peter J. O'Dwyer, Matthew L. Hemming, Anastasia Wyce, Michael T. McCabe, Geoffrey I. Shapiro, Antara Datta, Thierry Horner, Philippe A. Cassier, Sarina Anne Piha-Paul, Sophie Cousin, Christophe Le Tourneau, Brandon E. Kremer, Ruth Plummer, Christopher A. French, Ahmed Khaled, Vicki L. Keedy, Jose Manuel Trigo, Johann S. de Bono, Yuehui Wu, Arindam Dhar, Geraldine Ferron-Brady, Marie-Paule Sablin, Shawn W. Foley, Irene Braña Garcia
Publikováno v:
International Journal of Cancer. 150:993-1006
Molibresib is an orally bioavailable, selective, small molecule BET protein inhibitor. Results from a first time in human study in solid tumors resulted in the selection of a 75 mg once daily dose of the besylate formulation of molibresib as the reco
Autor:
Jean-Yves Blay, Thierry Horner, Seock-Ah Im, Peter J. O'Dwyer, Christine L. Hann, Christophe Le Tourneau, Sarina Anne Piha-Paul, Victor Moreno, Geraldine Ferron-Brady, Arindam Dhar, Brandon E. Kremer, Irene Braña Garcia, Johann S. de Bono, Arun Azad, Geoffrey I. Shapiro, Sophie Cousin, Jose Manuel Trigo, Antara Datta, Yuehui Wu
Publikováno v:
Journal of Clinical Oncology. 38:3618-3618
3618 Background: Molibresib is an orally available, small molecule bromodomain and extra-terminal domain (BET) protein inhibitor under investigation for treatment of advanced solid tumors. Methods: This was an open-label, single- and repeat-dose, 2-p
Autor:
Jason Trama, Eli Mordechai, Antara Datta, Martin E. Adelson, Yakov Mogilevkin, Abraham Ami Sidi
Publikováno v:
BMC Cancer, Vol 11, Iss 1, p 234 (2011)
BMC Cancer
BMC Cancer
Background Bladder cancer is a significant healthcare problem in the United States of America with a high recurrence rate. Early detection of bladder cancer is essential for removing the tumor with preservation of the bladder, avoiding metastasis and
Publikováno v:
Cancer Research. 70:4619-4619
Bladder cancer is a significant healthcare problem in the USA with a high recurrence rate. More than 90% of bladder cancers are transitional cell carcinomas (TCC). About 75% of TCC present as superficial tumors, of which 50-70% of tumors will recur a